ナカヤマ リョウコ
Nakayama Ryoko
中山 亮子 所属 鶴見大学 歯学部 歯学科 病理学 職種 助教 |
|
論文種別 | 【査読あり】 研究論文(学術雑誌) |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo |
掲載誌名 | 正式名:International Journal of Molecular Sciences ISSNコード:14220067 |
出版社 | Multidisciplinary Digital Publishing Institute |
巻・号・頁 | 17(3),pp.272-272 |
著者・共著者 | Yasukawa, Masaaki,Fujihara, Hisako,Fujimori, Hiroaki,Kawaguchi, Koji,Yamada, Hiroyuki,Nakayama, Ryoko,Yamamoto, Nanami,Kishi, Yuta,Hamada, Yoshiki,Masutani, Mitsuko |
発行年月 | 2016/02 |
概要 | Cisplatin is a commonly used chemotherapeutic drug for treatment of oral carcinoma, and combinatorial effects are expected to exert greater therapeutic efficacy compared with monotherapy. Poly(ADP-ribosyl)ation is reported to be involved in a variety of cellular processes, such as DNA repair, cell death, telomere regulation, and genomic stability. Based on these properties, poly(ADP-ribose) polymerase (PARP) inhibitors are used for treatment of cancers, such as BRCA1/2 mutated breast and ovarian cancers, or certain solid cancers in combination with anti-cancer drugs. However, the effects on oral cancer have not been fully evaluated. In this study, we examined the effects of PARP inhibitor on the survival of human oral cancer cells in vitro and xenografted tumors derived from human oral cancer cells in vivo. In vitro effects were assessed by microculture tetrazolium and survival assays. The PARP inhibitor AZD2281 (olaparib) showed synergetic effects with cisplatin in a dose-dependent manner. Combinatorial treatment with cisplatin and AZD2281 significantly inhibited xenografted tumor growth compared with single treatment of cisplatin or AZD2281. Histopathological analysis revealed th |
DOI | 10.3390/ijms17030272 |
PermalinkURL | http://www.mdpi.com/1422-0067/17/3/272 |